Frederic Zenhausern, PhD, MBA
Dr. Zenhausern is the director of the Center for Applied NanoBioscience and Medicine (ANBM), as well as of Biomedical Engineering at the University of Arizona College of Medicine – Phoenix. Prior to joining The University of Arizona, professor Zenhausern was director of the Center for Applied NanoBioscience at the Arizona State University’s (ASU) Biodesign Institute. While at Arizona State University, he was co-founder and director for the first phase of the Flexible Display Center at ASU MacroTechnology Works. Dr. Zenhausern was also tenured professor with both the Electrical Engineering Department and the School of Materials at ASU’s Ira A. Fulton School of Engineering. Dr. Zenhausern is a senior investigator and associate director of Molecular Diagnostics and Target Validation Division at the Translational Genomics Research Institute (TGen).
Another of Dr. Zenhausern’s responsibilities is leading the Laboratory for Research in Personalized Medicine at HonorHealth and Clinical Research Institute. Together with Dr. Jeffrey Trent, Dr. Zenhausern co-founded Nanobiomics Inc. which merged with the Molecular Profiling Institute that was acquired by Caris Diagnostics in 2008. Dr. Zenhausern also serves on several corporate scientific boards and international consortia in life sciences.
Dr. Zenhausern received his BS in biochemistry from the University of Geneva, a MBA in finance from Rutgers University and his Doctorate of Science in Applied Physics from the department of Condensed Physics Matter at the University of Geneva in Switzerland. Dr. Zenhausern has co-authored more than 70 scientific publications and is named on more than a dozen issued U.S. patents. Dr. Zenhausern has held several corporate research position, including: visiting scientist (IBM T.J. Watson Research Center, NY), head of Physical Measurements Group (Firmenich Inc., NJ), vice president of Advanced Technology (Alpha-MOS America, Inc., NJ), and manager of Microdevice Physics (Motorola Labs, AZ).